Download link can be found at the bottom of the post. The first half of 2026 has reinforced a structural shift in how leading U.S. hospital systems engage with healthcare innovation. Hospital-linked venture activity is no longer best understood as a collection of isolated startup investments. It increasingly offers a practical view into how leading health systems expect care delivery to evolve. The visible investment activity across selected prominent U.S. hospital systems points toward a...

Artificial intelligence has become one of the defining themes in healthcare. Investors are pouring billions into AI-enabled diagnostics, drug discovery platforms, clinical decision support tools, and operational software. Strategic buyers are actively acquiring AI capabilities. Our own 2025 M&A Deal Report suggested that AI-related deals represented 42% of all healthcare and life sciences deals across the United States and Europe in 2025, up from 32% just two years earlier. What was once...

In life sciences, due diligence used to revolve around a central question. Does the science work. That question still matters. It always will. But it is no longer enough. Today, most assets that make it into a serious process already have credible science. They have data, a rationale, and a story that holds up at first glance. What determines the outcome of a deal now sits elsewhere. The real question has shifted. Can this actually scale, operate, and deliver in the real world. This is where...